# Materna Medical

> Materna Medical is a Mountain View, California women's health company building FDA-cleared medical devices for pelvic health across a woman's life. Its consumer product, Milli, is the first vaginal dilator that expands one millimeter at a time to treat vaginismus and painful intercourse; its clinical-stage Ellora obstetrical system is designed to pre-stretch pelvic floor muscles during labor to reduce childbirth injury. Led by CEO Tracy MacNeal, the company has raised roughly $82.6M to date.

- **Founded:** 2010
- **Headquarters:** Mountain View, California, United States
- **Founders:** Mark Juravic (Co-Founder), Michael Stewart (Co-Founder)
- **Team size:** ~35 employees
- **Products:** Milli, Ellora Obstetrical System (formerly Materna Prep)
- **Notable:** Developed Milli, the first and only vaginal dilator that expands one millimeter at a time., Secured FDA clearance for Milli to treat vaginismus and dyspareunia, then over-the-counter clearance in 2023., Reduced pelvic floor injury by 60% in a pilot study of its obstetrical device.

## Products & services

- **Milli** — The first and only vaginal dilator that expands incrementally, one millimeter at a time, with optional vibration. FDA-cleared to treat vaginismus and dyspareunia (painful intercourse). Launched 2019; cleared for over-the-counter sale in 2023. Priced at $395.
- **Ellora Obstetrical System (formerly Materna Prep)** — A clinical-stage expanding obstetrical dilator placed in the vagina during the first stage of labor to gradually pre-stretch pelvic floor muscles, aiming to make vaginal delivery easier, faster and safer while reducing pelvic muscle injury. Being evaluated in the EASE pivotal trial.

## Achievements

- Developed Milli, the first and only vaginal dilator that expands one millimeter at a time.
- Secured FDA clearance for Milli to treat vaginismus and dyspareunia, then over-the-counter clearance in 2023.
- Reduced pelvic floor injury by 60% in a pilot study of its obstetrical device.
- Raised roughly $82.6M to date across multiple rounds led by InnovaHealth Partners.
- Completed enrollment in the EASE pivotal trial of the Ellora obstetrical system in first-time mothers.
- Series B raised by a female CEO in a market where female founders receive ~2% of VC.

## Latest updates

- **2026-07** — Raised $5M in a Series B3 financing round led by InnovaHealth Partners, with Wavemaker360 Health and Band of Angels, to fund completion of the EASE pivotal trial and expand access to Milli.
- **2024-05** — Completed first close of a Series B2 financing round (~$5.7M of a $20M target), bringing total funding to roughly $57.6M at the time.
- **2024** — Completed enrollment in the EASE trial of the Ellora obstetrical system in first-time mothers.
- **2023** — Milli received FDA clearance for over-the-counter sale, removing the prescription requirement.
- **2022-08** — Raised $22M Series B led by InnovaHealth Partners to advance its women's pelvic health portfolio.

## Links

- Website: https://maternamedical.com
- LinkedIn: https://www.linkedin.com/company/materna-medical/
- Twitter/X: https://twitter.com/materna_medical
- YouTube: https://www.youtube.com/@hellomilli_
- Instagram: https://www.instagram.com/hellomilli_/

---

Profile page: https://yespress.io/materna-medical
Published by YesPress — https://yespress.io
Last updated: 2026-07-11